Spots Global Cancer Trial Database for A Phase 1 Dose Escalation Study of IPI-493
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1 Dose Escalation Study of IPI-493
Official Title: A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of IPI-493 Orally Administered to Patients With Advanced Malignancies
Study ID: NCT00724425
Conditions
Interventions
Study Description
Brief Summary: IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.
Detailed Description: Hsp90 controls the proper folding, function, and stability of various "client" proteins within cells. Many of the clients of Hsp90 (such as Akt, Bcr-Abl, EGFR, Flt-3, c-Kit and PDGFR α) are oncoproteins or important cell-signaling proteins, and therefore are critical for tumor cell growth and survival. Inhibition of Hsp90 results in degradation of these proteins, which abrogates growth and survival signaling and leads to tumor cell death.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Premiere Oncology, Arizona, Scottsdale, Arizona, United States
San Diego Pacific Oncology and Hematology Associates, Encinitas, California, United States
Premiere Oncology, California, Santa Monica, California, United States
Univeristy of Colorado Health Science Center, Aurora, Colorado, United States
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Contact Details
Name: Robert Ross, MD
Affiliation: Infinity Pharmaceuticals, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
